A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis
Overweight or Obesity

Interventions

DRUG: Tirzepatide

Sponsor

Eli Lilly and Company